Can Complementary 68Ga-DOTATATE and 18F-FDG PET/CT Establish the Missing Link Between Histopathology and Therapeutic Approach in Gastroenteropancreatic Neuroendocrine Tumors?

被引:79
|
作者
Simsek, Duygu Has [1 ]
Kuyumcu, Serkan [1 ]
Turkmen, Cuneyt [1 ]
Sanli, Yasemin [1 ]
Aykan, Faruk [2 ]
Unal, Seher [1 ]
Adalet, Isik [1 ]
机构
[1] Istanbul Univ, Istanbul Fac Med, Dept Nucl Med, TR-34390 Istanbul, Turkey
[2] Istanbul Univ, Inst Oncol, Dept Med Oncol, TR-34390 Istanbul, Turkey
关键词
gastroenteropancreatic neuroendocrine tumor; Ga-68-DOTATATE; F-18-FDG; Ki67; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; KI-67; GUIDELINES;
D O I
10.2967/jnumed.114.142224
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Gastroenteropancreatic neuroendocrine tumors (GEPNETs) are indolent neoplasms presenting unpredictable and unusual biologic behavior that causes many clinical challenges. Tumor size, existence of metastasis, and histopathologic classification remain incapable in terms of treatment decision and prognosis estimation. This study aimed to compare Ga-68-DOTATATE and F-18-FDG PET/CT in GEPNETs and to investigate the relation between the complementary PET/CT results and histopathologic findings in the management of therapy, particularly in intermediate-grade patients. Methods: The relation between complementary Ga-68-DOTATATE and F-18-FDG PET/CT results of 27 GEPNET patients (mean age, 56 y; age range, 33-79 y) and histopathologic findings was evaluated according to grade and localization using standardized maximum uptake values and Ki67 indices. Grade 2 (G2) patients were further evaluated in 2 groups as G2a (3%- 9%) and G2b (10%-20%) according to Ki67 indices. Results: The sensitivity of Ga-68-DOTATATE and F-18-FDG PET/CT was 95% and 37%, respectively, and the positive predictive values were 93.8% and 36.2%, respectively. The sensitivity in detecting liver metastasis, lymph nodes, bone metastasis, and primary lesion was 95%, 95%, 90%, and 93% for Ga-68-DOTATATE and 40%, 28%, 28%, and 75% for F-18-FDG, respectively. Statistically significant differences were found between grades 1-2, 2a-2b, and 1-2b with respect to Ga-68-DOTATATE PET/CT as well as between 1-2a and 1-2b with respect to F-18-FDG PET/CT. However, no statistical differences were found between 1 and 2a (P > 0.05) for Ga-68-DOTATATE and 2a and 2b (P = 0.484) for F-18-FDG. The impact of the combined F-18-FDG and Ga-68-DOTATATE PET/CT on the therapeutic decision was 59%. Conclusion: Combined Ga-68-DOTATATE and F-18-FDG PET/CT is helpful in the individual therapeutic approach of GEPNETs and can overcome the shortcomings of histopathologic grading especially in intermediate-grade GEPNETs.
引用
收藏
页码:1811 / 1817
页数:7
相关论文
共 50 条
  • [1] A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors
    Kayani, Irfan
    Conry, Brendon G.
    Groves, Ashley M.
    Win, Thida
    Dickson, John
    Caplin, Martyn
    Bomanji, Jamshed B.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (12) : 1927 - 1932
  • [2] Comparison of the application of 18F-FDG and 68Ga-DOTATATE PET/CT in neuroendocrine tumors: A retrospective study
    Hu, Xianwen
    Li, Dandan
    Wang, Rui
    Wang, Pan
    Cai, Jiong
    MEDICINE, 2023, 102 (19) : E33726
  • [3] The Combined Interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in Metastatic Gastroenteropancreatic Neuroendocrine Tumors A Classification System With Prognostic Impact
    Hayes, Aimee R.
    O'Mahony, Luke Furtado
    Quigley, Ann-Marie
    Gnanasegaran, Gopinath
    Caplin, Martyn E.
    Navalkissoor, Shaunak
    Toumpanakis, Christos
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (01) : 26 - 35
  • [4] Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms
    Zhang, Panpan
    Yu, Jiangyuan
    Li, Jie
    Shen, Lin
    Li, Nan
    Zhu, Hua
    Zhai, Shizhen
    Zhang, Yan
    Yang, Zhi
    Lu, Ming
    CONTRAST MEDIA & MOLECULAR IMAGING, 2018,
  • [5] Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors
    Panagiotidis, Emmanouil
    Alshammari, Alshaima
    Miehopoulou, Sofia
    Skoura, Evangelia
    Naik, Keval
    Maragkoudakis, Emmanouil
    Mohmaduvesh, Mullan
    Al-Harbi, Mohammed
    Belda, Maria
    Caplin, Martyn E.
    Toumpanakis, Christos
    Bomanji, Jamshed
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (01) : 91 - 96
  • [6] Combination of 68Ga-DOTATATE and 18F-FDG PET/CT in Advanced Gastroenteropancreatic Neuroendocrine Tumours (GEPNET) - Clinical and Prognostic Implications
    O'Mahony, Furtado L.
    Miah, L.
    Narayan, A.
    Kamieniarz, L.
    Leigh, C.
    Bhatt, A.
    Cox, N.
    Mandair, D.
    Caplin, M.
    Navalkissoor, S.
    Hayes, A. R.
    Toumpanakis, C.
    NEUROENDOCRINOLOGY, 2019, 108 : 59 - 59
  • [7] A Case of Brown Tumor on 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT
    Yao, Xilan
    Ou, Xiaohong
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (01) : 88 - 89
  • [8] 68Ga-DOTATATE and 18F-FDG PET/CT in a Rapidly Progressing Lymphoma
    Parihar, Ashwin Singh
    Wahl, Richard L.
    Jahromi, Amin H.
    CLINICAL NUCLEAR MEDICINE, 2025, 50 (01) : e64 - e65
  • [9] 68Ga-DOTATATE PET/CT in Gastroenteropancreatic Neuroendocrine Tumors (NETs): Pearls and Pitfalls
    Metser, Ur
    Murad, Vanessa
    Ortega, Claudia
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [10] Comparison of 18F-FDG, 68Ga-FAPI, and 68Ga-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor
    Cheng, Zhaoting
    Zou, Sijuan
    Cheng, Siyuan
    Song, Shuang
    Zhu, Xiaohua
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (09) : 764 - 765